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Abstract 
In this in-depth review, we examine the worldwide epidemiology of Systemic lupus 
erythematosus (SLE) and summarise current knowledge on the influence of race/ethnicity on 
clinical manifestations, disease activity, damage accumulation and outcome in SLE. 
Susceptibility to SLE has a strong genetic component and trans-ancestral genetic studies have 
revealed a substantial commonality of shared genetic risk variants across different genetic 
ancestries which predispose to the development of SLE. The highest increased risk of 
developing SLE is observed in black individuals (incidence 5- to 9-fold increased, prevalence 
2- to 3-fold increased), with an increased risk also observed in South Asians, East Asians and 
other non-white groups, compared to white individuals. Black, East Asian, South Asian and 
Hispanic SLE individuals tend to develop more severe disease with a greater number of 
manifestations and accumulate damage from lupus more rapidly. Increased genetic risk 
burden in these populations, associated with increased autoantibody reactivity in non-white 
SLE, may explain the more severe lupus phenotype. Even after taking into account socio-
economic factors, race/ethnicity remains a key determinant of poor outcome such as end-
stage renal failure and mortality in SLE. Community measures to expedite diagnosis through 
increased awareness in at-risk racial/ethnic populations and ethnically personalised treatment 
algorithms may help in future to improve long term outcomes in SLE. 
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Introduction 
Over recent years our understanding of Systemic Lupus Erythematosus (SLE) has advanced 
at the level of its epidemiology, genetic susceptibility and depth of understanding of 
molecular mechanisms underlying its pathogenesis. These advances have been achieved 
through national and international collaboration between SLE researchers and clinicians, in 
conjunction with the harnessing of post-genome era technology. Early studies on the 
influence of ethnicity on the incidence and prevalence of SLE are thoroughly described in a 
key review by Danchenko et al [1], and a subsequent analysis of SLE epidemiological studies 
including the effect of ethnicity on clinical manifestations was last comprehensively 
conducted by Borchers et al [2]. This current review will concentrate on highlighting and 
contrasting additional information from subsequent studies. 
 
Worldwide epidemiology of SLE 
Reliable studies of incidence and prevalence of SLE remain few and far between, due to 
problems of cohorts being incomplete or drawn from populations which are not closed or for 
which the boundaries are unclear. In many countries a lack of high quality census data has 
prohibited many cohort studies from reporting accurate incidence and prevalence figures, 
even where consistent patient registries have been built up over a number of years. In 
countries with more extensive public health systems, accurate SLE patient registries have in 
the past provided important information on incidence and prevalence including studies from 
Denmark, Finland, Norway, Sweden and UK [3-7]. More recent studies have benefited from 
improved definitions of SLE diagnosis based first on the 1997 American College of 
Rheumatology (ACR) classification criteria for SLE, and the more recent 2012 Systemic 
Lupus Collaborating Clinics (SLICC) revision of the ACR criteria. However few studies have 
employed capture-recapture technique to improve validity. Two recent large and 
comprehensive studies from Michigan and Georgia cohorts in the US [8, 9], showed 
remarkable consistency and reported the incidence of SLE as 5.5 and 5.6 per 100,000 
respectively and the prevalence of SLE as 72.8 and 73.0 per 100,000, based on data from 
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2002-2004. Comparisons of studies across the world shows a wide range of prevalence from 
25-28 per 100,000 in Northern Ireland, Finland and Denmark [3, 7, 10] to 149 in Alaska [11] 
and 159 in Puerto Rico [12]. These studies are summarised in Figures 1 and 2. Direct 
comparisons between countries are problematic, because of a clear increase in both the 
incidence and prevalence of SLE over time, as shown in Fig. 3. A recent large UK study 
reported a relatively stable overall incidence of 4.9 per 100,000 per year over the time period 
1999-2012, while the prevalence of SLE rose steadily from 65.0 in 1999 to 97.0 per 100,000 
in 2012 [13]. Comparison of studies across the world from the 1970s through to present day 
(Fig. 2) illustrate that the prevalence of SLE has risen over time with studies in the 1970s 
reaching a maximum prevalence of 40 per 100,000, while several large studies performed 
since 2000 have reported point prevalence of 100 per 100,000 or more [12-15]. The incidence 
of SLE has not risen over time to the same extent, but there are still a significant number of 
recent studies from UK, USA and Taiwan with incidence rates ranging from 4.8 to 7.2 per 
100,000, a level not seen in early studies. This rise in prevalence is a feature of a number of 
studies and presumably reflects improved diagnosis over time as well as improved survival 
rates, alongside the lifelong chronicity of the illness. Although the SLICC modification of the 
ACR classification criteria for SLE has not yet been used by any of the currently reported 
epidemiological studies, it is likely to increase the diagnostic rate for SLE further [16]. 
 
Defining race, ethnicity and ancestry in clinical studies 
Although race and ethnicity are terms that are commonly used in medical studies, their 
definition is complex. The concept “race” originally arose to group individuals by biological 
differences such as skin colour, with associated social and culture differences. However the 
term ran into difficulties when describing increasingly mixed populations such as in the USA. 
A later concept of “ethnicity” emphasised cultural, social and religious qualities, as opposed 
to genetic ancestry. However both race and ethnicity are fluid, and perceived racial or ethnic 
groups change over time. Genetic studies often use the term “ancestry”, by which individuals 
are categorised according to the origins of their ancestors. Ancestry is usually defined 
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geographically (e.g. East Asian, sub-Saharan African, northern European), and self-reported 
ancestry tends to correlate reasonably well with genetically-determined ancestry. However 
ancestry is a multi-dimensional continuum with endless possible sub-refinements (e.g. 
Norwegian versus Scandinavian) [17]. In practice all three terms of race, ethnicity and 
ancestry are interlinked. US government guidelines for reporting race and ethnicity include 5 
minimum categories of race (American Indian/ Alaska Native (AIAN), Asian, Black/African 
American, Hawaiian/Pacific Islander and white), while Hispanic/Latino individuals are 
categorised separately under ethnicity, referring to people of Mexican, South or Central 
American or other Spanish culture, regardless of race [18]. “Amerindian” is a broad ancestral 
term which refers to indigenous people of the Americas, including Central or South America. 
Genetic analyses reveal that Hispanic individuals display ancestral genetic diversity, with 
Hispanics from Texas showing a significant proportion of Amerindian ancestral genes, 
whereas African and white European ancestral genes are more common in Hispanics from 
Puerto Rico [19, 20]. The Mestizo, studied under the ethnic grouping “Hispanic”, are 
individuals of combined European and Amerindian (usually indigenous Mexican/central 
American) ancestry. “Asian” is an ambiguous term since in the UK it usually refers to 
individuals from India, Pakistan, Bangladesh or neighbouring regions, while in the USA it 
usually refers to individuals of Chinese, Korean or Japanese origin. Hence in this article we 
distinguish between South Asian and East Asian, although these terms are generally not used 
in the source studies. 
 
Effect of race and ethnicity on incidence and prevalence of SLE 
A consistent finding across epidemiological studies is that SLE is significantly more common 
in black individuals and specific races and ethnicities compared to white individuals. This 
finding has been repeatedly confirmed in numerous studies across the USA through to 
modern day [8, 9, 21-23]. Similar findings were reported in UK studies based in Birmingham 
and Nottingham [4, 24], which showed 5- to 9-fold increased incidence and 5- to 10-fold 
increase in prevalence of SLE in Afro-Caribbeans, as well as a 1.2- to 6-fold increase in 
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incidence and 2- to 2.4-fold increase in prevalence in South Asian individuals compared to 
white individuals. Further attempts to define ethnic groups at risk of SLE are complicated by 
lack of racial and genetic homogeneity for certain ethnicities. SLE in Hispanic individuals 
has been studied extensively in the LUMINA (Lupus in Minorities: Nature vs. nurture) cohort 
studies [20]. In Canada, a 2-fold increase in incidence and prevalence of SLE was observed 
in native American Indian individuals compared to whites [25], and a later study observed 
that American Indian and Alaska Native individuals demonstrated an incidence of 7.4 per 
100,000 and prevalence of 178 per 100,000 of SLE, which are some of the highest rates 
recorded and comparable to African Americans [11]. Although substantial information is 
available about SLE in African ancestry individuals living in the Americas and Europe, there 
are currently no accurate studies of the incidence or prevalence of SLE in Africa, the Middle 
East or South Asia. A recent UK study, which is one of few to subdivide South Asian 
ethnicity into subgroups, found that Indian ethnicity is associated with higher incidence (9.9 
per 100,000) and prevalence of SLE (193 per 100,000), although not as high as in Afro-
Caribbeans (incidence 31.5 and prevalence 518 per 100,000). The incidence (10.0 per 
100,000) of SLE was higher in UK Pakistanis, although the prevalence was not increased 
(143 per 100,000) [13]. The incidence and prevalence of SLE in UK Bangladeshi individuals 
was apparently not increased compared to whites. However a problem with this study is the 
high percentage of individuals with ‘unknown’ or ‘unclassified’ ethnicity. Subgroup analysis 
of the Michigan Lupus registry suggests that the incidence of SLE in individuals of Arab or 
Chaldean origin was 2.1-fold increased compared to white individuals [26]. 
Early studies anecdotally suggested a low prevalence of SLE in Africa. Although 
there remains a lack of high quality epidemiology studies from African countries, data on 
migrants shows that the incidence and prevalence of SLE is high in Africans, Caribbeans and 
South Asians who have migrated to the UK [4, 27]. Recent evidence suggests that SLE and 
lupus nephritis are a significant health burden in Africa [28, 29]. An interesting study showed 
that rates of SLE autoantibody positivity were similar in a cohort of healthy Gullah 
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individuals (African Americans from the Sea Islands of South Carolina of low genetic 
admixture) compared to a genetically similar population of women from Sierra Leone [30]. 
 No studies directly comparing diverse populations have reported statistically 
significant variance from the gender bias towards female individuals being affected by SLE. 
In studies across multiple populations the percentage of females affected ranged from 88.3 to 
96.2%, giving a female:male gender ratio centred around 9:1, ranging from 7.5:1 in Curaçao 
to 23:1 in Oman and 25:1 in Hispanic individuals in a USA cohort [31-33]. 
 
Genetics, ancestry and SLE 
SLE is known to have a strong genetic link with a heritability of ~66%. The twin 
concordance rate for SLE is 24% in monozygotic twins compared to 2% in dizygotic twins 
[34]. SLE has a sibling recurrence risk ratio (λs) of 29 compared to 5.3 in rheumatoid arthritis 
(RA) [35]. Since the advent of genome wide association studies (GWAS), at least 52 genetic 
loci with strong evidence of association with susceptibility to SLE have been confirmed [36-
41]. Although cohort size is a major factor, which has increased the power of these studies to 
find genetic associations, the veracity of these large scale studies is also underpinned by 
radical improvements in computer science in data storage, quality control, statistical and 
analytical techniques. The region of the genome with by far the strongest association with 
susceptibility to SLE is the major histocompatibility complex (MHC), located on 
chromosome 6. Prior to GWAS scale studies the 8.1 ancestral haplotype has long been known 
to be associated with endocrine, gastrointestinal, haematologic/immunologic autoimmune 
diseases and sarcoidosis through to multiple connective tissue diseases including SLE. This 
MHC haplotype extends to include HLA-A1*01:01, B*08:01, C4AQ0, C4B1, DRB1*03:01, 
DQA1*05:01, DQB1*02:01 (A1::DQ2 in older nomenclature), encompassing two significant 
class III genetic variants, complement C4A null as well as the TNF-308A allele. Major 
confounding factors affecting MHC genetic association studies are long-range linkage 
disequilibrium (LD) and duplications of regions leading to copy number variation (CNV) and 
pseudogenes. Only the largest most recent genetic studies using techniques including trans-
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ancestral mapping have sufficient power to dissect which genes within the MHC are 
responsible for disease susceptibility rather than finding associations with the whole MHC 
block. The highest HLA association with SLE has been observed for HLA-DRB1*03:01, with 
a weaker effect observed for HLA-DRB1*15:01 [42]. However although this study including 
multiple cohorts from different countries including the USA, the individuals included were 
predominantly of European ancestry. Trans-ancestral mapping of UK, Spanish and Filipino 
SLE patients showed differential MHC signals according to ancestry [43]. Independent 
association of HLA-DRB1*08:01 was seen in Spanish SLE but not in other groups, in 
addition to known association with HLA-DRB1*03:01 and HLA-DRB1*15:01. SNPs with the 
best odds ratio in Spanish SLE clustered around the DNA repair gene MSH5. The top SNP in 
Filipino SLE, rs9271366, located between HLA-DRB1 and HLA-DQA1, may represent 
association with HLA-DRB1*15:02. The risk haplotype with the top 3 independent MHC 
SNPs was also more common in Filipino SLE, consistent with the increased prevalence of 
SLE in East Asian population. The association of HLA-DRB1*03:01 with SLE is stronger in 
anti-Ro and anti-La antibody positive SLE, suggesting that this HLA haplotype promotes 
break of tolerance to Ro and La autoantigens, independently of its association with SLE [44]. 
Interestingly a study of black women with SLE could not confirm association of SLE with 
HLA-DRB1*03:01 and HLA-DRB1*15:01 in this population, although of the four 
independently associated SNPs, two are located in MHC class II region consistent with other 
studies in Europeans and East Asians [38, 42]. A relatively small study suggested that HLA-
DRB1*15:03 and HLA-DRB1*08 were more frequent in African American and Hispanic SLE 
individuals respectively [45]. These dissimilarities are in keeping with the heterogeneity of 
the extended MHC locus and will require larger studies to fully dissect differences between 
ancestries in terms of MHC region mediated susceptibility to SLE. By comparison, in 
rheumatoid arthritis five key amino acid residues in HLA-DRβ1, HLA-B and HLA-DPβ1 are 
able to explain almost completely the genetic susceptibility to RA conferred by the HLA 
region [46]. Trans-ancestral studies in RA show that these amino acids confer shared effects 
in Asian individuals [47]. Similar in-depth trans-ancestral analyses of the MHC including 
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HLA amino acid variation in SLE are currently lacking. Genes encoding complement C4 and 
TNF-alpha are also located within the MHC region. A study of northern European (UK) and 
southern European (Spanish) SLE populations showed that C4 CNV was not an independent 
risk factor for SLE susceptibility in either population [48]. A meta-analysis suggested that the 
TNF promoter -308A/G polymorphism may increase risk of SLE in European populations, 
but not in Asian populations [49]. 
 Outside of the MHC, recent GWAS studies have superseded older candidate gene 
studies and have shown over 40 genes associated with SLE in European populations reaching 
genome-wide significance (p < 5×10
−8
) [36]. Comparison with GWAS in Han Chinese 
individuals initially suggested some differences in gene associations [38], with associations 
found in RASGRP3, ETS1 and WDFY4/LRRC18 which had not been previously identified in 
Europeans and association with IKZF1 and SLC15A4 for which early European data was only 
suggestive of association. These differences are largely due to altered risk variant frequency 
with apparently East Asian specific variants being more common in East Asians than in 
Europeans and vice versa. However as GWA studies become larger and larger, some risk 
variants which are rarer in certain populations are likely to be revealed as part of a 
commonality of genetic susceptibility across multiple ancestries, and this has proven to be the 
case for all the above genes except RASGRP3, which remains the only gene associated with 
Chinese SLE not to be replicated in Europeans at time of writing [36]. A fresh meta-analysis 
of European and Chinese GWAS data [41] confirmed substantial commonality in shared risk 
variants between the two populations. This is similar to trans-ancestral GWAS in RA which 
showed >80% of the heritability attributed to 101 RA risk loci was shared between 
Europeans and Asians [50]. Overall, risk variant frequencies were higher in Chinese 
individuals than in Europeans in keeping with the higher prevalence of SLE in Chinese 
individuals, suggesting a greater SLE genetic risk burden in East Asia. GWAS in Amerindian 
SLE identified association with IRF5, ITGAM, STAT4, TNIP1, NCF2 and IRAK1, which were 
all previously identified in European SLE GWAS [36]. However it was striking that the 
association with IRF5 (interferon response factor-5) was stronger than the HLA association in 
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this cohort. This study also identified rs4917385 in proximity of USMG5 with eQTL 
evidence that this SNP affects USMG5 expression as an Amerindian specific susceptibility 
locus. A candidate gene study in African American individuals suggested MECP2, MBL2 and 
PXK as European only-associated SLE susceptibility genes [51]. Results of an ongoing 
GWAS in African ancestry SLE are not yet available, but will further inform our 
understanding of ancestral differences in genetic susceptibility to SLE once available. Trans-
ancestral fine mapping studies of individuals genes are rare but informative. They illustrate 
that although the most strongly associated SNPs vary with ancestry, common risk haplotypes 
can be identified across different ancestries for example for TNFSF4 (which encodes OX40L, 
an activatory ligand for OX40 receptor on T lymphocytes) [52] and the IL2/IL21 locus [53]. 
Functional genetic studies have also begun to elucidate the immunological mechanisms of 
SLE susceptibility variants in ancestrally diverse populations [54, 55]. 
 A critical component of modern genetic studies is the use of ancestry-informative 
markers (AIMs), which measure genetic admixture to more accurately account for the effect 
of ancestry when studying genetic susceptibility to SLE. AIMs are necessary to exclude 
genetic variants whose apparent association with SLE is merely due to a confounding 
association with ancestral grouping. AIMs can be also used to probe for interaction between 
specific genes and ancestry in development of SLE in different ancestral groups. Using this 
method, Amerindian admixture was modestly correlated with increased numbers of risk 
alleles in a study of 16 confirmed genetic susceptibility loci [56].  
Racial differences in gene expression have been reported, with high expression of 
TLR9 and DNA methyltransferase DNMT3A observed in African American SLE compared to 
other ethnicities, associated with higher serum levels of TNF and IL-6 [57, 58]. 
 
Effect of ethnicity on clinical features and disease activity 
Many studies have examined whether ethnicity affects clinical phenotype in SLE. However 
these studies are complicated by the exceptional heterogeneity of disease manifestations in 
SLE: both diversity of organ involvement and heterogeneity between individuals. Differences 
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in reporting methods for clinical features as well as accurate recording of cumulative 
occurrence of manifestations add to the complexity of comparing studies. Previous reviews 
have compared clinical features across studies in different countries [2, 20]. Rates of ACR 
criteria manifestations were uniformly lower in Cervera and colleagues’ study of 1000 
predominantly white Europeans [59] compared to the GLADEL study by Pons-Estel et al and 
the LUMINA cohort by Alarcon et al [31]. Rates of clinical manifestations in a study of 
Hong Kong Chinese fell in between these studies [60]. These differences are perhaps more 
likely to be due to methodology than actual differences between ethnicities. Studies which 
specifically aimed to compare different races/ethnicities over the same time period and 
similar geographical areas are more likely to be accurate and representative. Thus it is 
generally accepted that individuals of African or Caribbean ancestry are more frequently 
affected by discoid rash (20-34%) compared to white Europeans (11-12%) [31, 61, 62], while 
photosensitivity may be more common in Europeans (81%) and individuals from Puerto Rico 
(90%) who have some European admixture compared to African Americans or Hispanics in 
Texas (both 56%) [20, 31, 63]. In UK studies, Afro-Caribbean individuals with SLE tended 
to develop renal disease earlier in the course of their illness and develop renal disease more 
frequently [64, 65]. Similar findings are reported in non-Europeans in France and in African 
Americans in the USA, Canada and Latin America [25, 61, 63, 66-68]. High levels of renal 
involvement are found in South Africa [69], Martinique [70], in Arab populations in Tunisia 
and Saudia Arabia [71, 72], and Asian populations including Chinese, Malaysians, Filipinos 
and Indians [60, 73-76]. A systematic review of glomerulonephritis in Africa identified lupus 
nephritis as one of the most common causes of secondary glomerular disease [28]. 
Individuals of African ancestry and Hispanics from Texas show more severe renal 
involvement with greater rates of progression to end-stage renal disease [66, 67], although 
Hispanic SLE patients from Texas developed more severe disease than those in Puerto Rico 
[77]. Renal disease is also more frequent in mestizo populations (mainly from Guatemala, 
Mexico and Peru) with SLE [61]. Rates of neuropsychiatric SLE (NPSLE) varied widely 
from cohort to cohort in older studies, with a range of 14% to 91%, rendering direct 
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comparisons between studies problematic. However the SLICC inception cohort has reported 
several studies in this area looking at individual NPSLE manifestations. In this cohort, 
seizure occurrence was 2.0-fold increased in African and 1.6-fold increased in Hispanic SLE 
compared to white individuals using multivariate analysis, with a tendency for seizures to be 
lower in frequency in Asian SLE individuals [78]. Mood disorders were lower in Asian SLE 
individuals, confirmed in South Korean patients [79],  however there was no effect of 
ethnicity/race on the prevalence of lupus headache [80]. However the SLICC cohort made no 
distinction between South and East Asia. Ethnicity/race has not been shown to predispose to 
thrombotic events [81, 82]. 
 Some studies have suggested that non-European SLE individuals show a higher 
frequency of positivity for specific autoantibodies such as anti-Sm [83]. Using a bead-based 
autoantibody assay African-American and Hispanic SLE patients showed positivity for a 
greater number of autoantibodies concomitantly: 53% of African American and 34% of 
Hispanic SLE individuals demonstrated 4 or more autoantibody specificities compared to 
19% of European SLE individuals [84]. Anti-chromatin, anti-Sm, anti-RNP, anti-dsDNA 
positivity was higher in African-American SLE and to a lesser extent Hispanic SLE 
compared to European SLE in this study. Other studies have confirmed the higher rate of 
anti-Sm and anti-RNP positivity in non-European ancestry SLE [20, 85, 86], but not all 
studies have confirmed this [61]. On the other hand anti-Ro and anti-La positivity tends to be 
similar across ethnicities. 
 
Impact of ethnicity on disease activity, damage accumulation and mortality 
Consistent with these trends that ethnicity/race influences rates of skin, renal, 
neuropsychiatric and immunologic manifestations, ethnicity impacts disease activity as a 
whole, with non-white individuals showing higher SLEDAI scores compared to whites both 
at baseline and over time [45, 87, 88]. Beyond the observation that clinical manifestations 
may be both more common and of greater severity in black and Hispanic individuals and to a 
varying degree Asian individuals, ethnicity has a knock-on effect on damage accumulation 
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and outcome over time. Doubling of creatinine and progression to end-stage renal failure 
(ESRF) is more common in African American and Hispanic individuals with lupus nephritis 
[89], and presentation with end-stage renal disease or rapid progression to ESRF in newly 
diagnosed SLE patients is significantly more common in African Americans [90]. Large 
studies observing more than 12000 lupus nephritis patients in the US ESRF registry have 
shown that African American SLE patients who reach end-stage renal failure have higher 
mortality rates than non-African populations, although one study suggested this effect may be 
related to median income [91] and a second study showed higher levels of cardiovascular 
events in the African American group [92]. Current data suggests that different ethnicities 
show similar allograft failure rates following renal transplantation for lupus nephritis [93]. In 
the SLICC cohort, African American SLE individuals showed the highest rates of 
progression of SLICC/ACR damage index (SDI), followed by Hispanic individuals, with the 
rate of progression in Asian SLE lower than for white individuals [94]. Other key factors 
predictive of damage accrual are age, disease activity including the number of flares and 
corticosteroid use [94, 95]. Black and Hispanic SLE individuals also respond more slowly to 
treatment and show slower falls in disease activity over time compared to white patients [96]. 
Increased rates of damage accumulation in African ancestry SLE is of major concern, 
because it has been consistently shown that damage score at baseline and damage accrual 
rates are a major predictor of mortality in SLE and consistent with this mortality is higher in 
African individuals with SLE [97-99]. A meta-analysis of mortality rates in SLE showed 
comparable rates between Asian studies in China and Taiwan compared to Europe and North 
America [100]. 
Interestingly there is some evidence of differential response to therapy according to 
ethnic group, although few studies have examined this issue systematically. African and 
Hispanic SLE patients showed greater response to rituximab compared to other groups [101]. 
Black and mixed-race SLE individuals showed poorer response to intravenous 
cyclophosphamide [102, 103]. Future randomised controlled trials (RCT) which include 
genotype data on study participants will be better placed to dissect these issues by measuring 
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genetic admixture instead of self-reported race/ ethnicity, especially in the case of mixed-race 
individuals who may be incorrectly categorised. 
 
Socio-economic factors 
In many countries where private health care predominates, including the US, poorer access to 
health care is self-evidently linked to worse outcome and morbidity. Thus a number of 
studies have attempted to distinguish the effect of ethnicity from socio-economic factors such 
as employment status, annual income, education level and social support network. General 
consensus from these studies is that although socio-economic factors play a definite role in 
worse outcome especially in SLE individuals with renal disease [91], ethnicity still acts as an 
independent risk factor for increased prevalence and severity of disease and worse outcome 
[45, 65, 67, 104]. This effect of ethnicity above and beyond socio-economic factors also 
remains true in the UK, where health care is primarily publically funded [105]. This evidence 
supports the notion that genetic-determined ancestry and possibly environmental factors 
related to ethnicity are involved in biological processes which increase SLE prevalence and 
disease severity. 
 
Comparison with other autoimmune diseases 
These effects of race/ethnicity, which have been strongly observed for SLE as described 
above, are specific to SLE. Although the incidence and prevalence of RA shows variation in 
different countries, there is a lack of evidence for a significant effect of race/ ethnicity in RA 
[106]. Similarly the systemic vasculitides, which themselves can be difficult to classify, vary 
in incidence and prevalence in different countries [107], although specific types of vasculitis 
show well known regional distributions, for example Behçet’s disease in Turkey and the Silk 
Road [108], and Takayasu’s disease in the Far East. It is worth noting that multiple sclerosis 
(MS) shows inversion in terms of race/ethnicity in comparison to SLE, since MS is 
substantially more common in white individuals compared to black or South Asian 
populations, consistent with the geographical distribution of white populations [109, 110]. 
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Conclusions 
The overall message from an extensive body of literature is consistent: ancestry, race and 
ethnicity together have a major effect on the way in which SLE manifests. Black, Asian and 
Hispanic SLE individuals tend to develop more severe disease, a greater number of 
manifestations and accumulate damage from lupus more rapidly. Even after taking into 
account socio-economic factors, race/ethnicity remains a key determinant of poor outcome 
such as end-stage renal failure and mortality in SLE. Ongoing genetic studies suggest an 
increased genetic risk burden in these populations associated with increased autoantibody 
reactivity in non-European SLE, which may partly explain the more severe lupus phenotype. 
Subgroup analyses from RCTs have shown that different ethnic groups respond differentially 
to therapeutic interventions. Community measures to improve early diagnosis through 
increased awareness in at-risk racial/ethnic communities, together with more ethnically 
personalised treatment algorithms may be required in future to reduce the severity of SLE in 
high risk populations and thus improve long term outcome. 
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Figure legends 
Fig. 1. Epidemiological studies of SLE in different countries 
Incidence (A) and prevalence (B) of SLE in epidemiological studies across the world. Where 
multiple studies are available for a country or region, the largest and/or most recent data are 
represented. Error bars show 95% confidence intervals for incidence and prevalence. Where 
confidence intervals were not published, they were calculated based on case number and 
incidence/prevalence. *Countries/administrative regions with nationwide data. 
 
Fig. 2. Choropleth map showing prevalence of SLE around the world 
Countries lacking prevalence data are shown in grey. Coloured circles highlight prevalence 
data from Puerto Rico, Martinique and Hong Kong. 
 
Fig. 3. Bubble chart summarising studies of incidence and prevalence of SLE over time 
Linear regression models (white line) were calculated in R, with region within 95% 
confidence interval shaded grey. 
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